Joyce A. Cramer

28.2k total citations · 9 hit papers
225 papers, 22.4k citations indexed

About

Joyce A. Cramer is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Family Practice. According to data from OpenAlex, Joyce A. Cramer has authored 225 papers receiving a total of 22.4k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Psychiatry and Mental health, 119 papers in Pediatrics, Perinatology and Child Health and 27 papers in Family Practice. Recurrent topics in Joyce A. Cramer's work include Epilepsy research and treatment (120 papers), Pharmacological Effects and Toxicity Studies (106 papers) and Medication Adherence and Compliance (26 papers). Joyce A. Cramer is often cited by papers focused on Epilepsy research and treatment (120 papers), Pharmacological Effects and Toxicity Studies (106 papers) and Medication Adherence and Compliance (26 papers). Joyce A. Cramer collaborates with scholars based in United States, United Kingdom and Australia. Joyce A. Cramer's co-authors include Richard H. Mattson, Ami Claxton, Orrin Devinsky, Kimford J. Meador, Joseph F. Collins, Kenneth Perrine, Robert A. Rosenheck, Bruce P. Hermann, Anita Burrell and Anuja Roy and has published in prestigious journals such as New England Journal of Medicine, JAMA and American Journal of Psychiatry.

In The Last Decade

Joyce A. Cramer

223 papers receiving 21.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A systematic review of the associations between dose regimens and medication compliance

2001 1.9k citations Joyce A. Cramer et al. profile →
Medication Compliance and Persistence: Terminology and Definitions

2007 1.7k citations Joyce A. Cramer et al. Value in Health profile →
A Systematic Review of Adherence With Medications for Diabetes

2004 1.0k citations Joyce A. Cramer profile →
Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic Seizures

1985 853 citations Richard H. Mattson, Joyce A. Cramer et al. profile →
How Often Is Medication Taken as Prescribed?

1989 823 citations Joyce A. Cramer profile →
Development and Cross‐Cultural Translations of a 31‐Item Quality of Life in Epilepsy Inventory

1998 600 citations Joyce A. Cramer, Kenneth Perrine et al. Epilepsia profile →
A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases

2006 538 citations Joyce A. Cramer et al. Value in Health profile →
Development of the Quality of Life in Epilepsy Inventory

1995 524 citations Orrin Devinsky, Joyce A. Cramer et al. Epilepsia profile →
A Comparison of Valproate with Carbamazepine for the Treatment of Complex Partial Seizures and Secondarily Generalized Tonic–Clonic Seizures in Adults

1992 521 citations Richard H. Mattson, Joyce A. Cramer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joyce A. Cramer United States	74	11.0k	8.9k	3.9k	2.6k	1.9k	225	22.4k
Wayne A. Ray United States	75	3.4k 0.3×	2.0k 0.2×	467 0.1×	314 0.1×	2.3k 1.2×	215	21.5k
Nick Freemantle United Kingdom	80	3.0k 0.3×	1.2k 0.1×	1.1k 0.3×	438 0.2×	3.3k 1.8×	498	29.3k
Ian Chi Kei Wong United Kingdom	61	3.1k 0.3×	3.4k 0.4×	267 0.1×	376 0.1×	1.0k 0.6×	668	16.8k
Roberto Bernabei Italy	90	5.3k 0.5×	1.3k 0.1×	575 0.1×	380 0.1×	4.3k 2.3×	516	35.8k
David G. Le Couteur Australia	70	1.4k 0.1×	1.1k 0.1×	749 0.2×	628 0.2×	2.4k 1.3×	405	19.2k
Edward M. Sellers Canada	73	3.6k 0.3×	3.1k 0.4×	130 0.0×	4.9k 1.9×	463 0.2×	423	28.5k
Paula A. Rochon Canada	73	3.0k 0.3×	991 0.1×	546 0.1×	210 0.1×	2.3k 1.3×	382	18.0k
Christine Miaskowski United States	86	2.2k 0.2×	8.5k 1.0×	188 0.0×	1.0k 0.4×	687 0.4×	689	31.7k
Thomas R. Einarson Canada	58	1.3k 0.1×	2.8k 0.3×	504 0.1×	225 0.1×	1.0k 0.6×	239	13.7k
Walter A. Rocca United States	99	10.2k 0.9×	2.2k 0.2×	71 0.0×	3.8k 1.4×	1.1k 0.6×	347	33.2k

Countries citing papers authored by Joyce A. Cramer

Since Specialization

Citations

This map shows the geographic impact of Joyce A. Cramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce A. Cramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce A. Cramer more than expected).

Fields of papers citing papers by Joyce A. Cramer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce A. Cramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce A. Cramer. The network helps show where Joyce A. Cramer may publish in the future.

Co-authorship network of co-authors of Joyce A. Cramer

This figure shows the co-authorship network connecting the top 25 collaborators of Joyce A. Cramer. A scholar is included among the top collaborators of Joyce A. Cramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyce A. Cramer. Joyce A. Cramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Neal, Welton, et al.. (2018). Adherence with Extended-Release Oxcarbazepine (Oxtellar XR®) vs. Immediate-Release Oxcarbazepine: Analysis of Pooled Data from Four National Pharmacy Claims Databases (P6.293). Neurology. 90(15_supplement). 1 indexed citations

Cramer, Joyce A., Fulton Velez, Kathryn Anastassopoulos, et al.. (2015). Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate. Epilepsy & Behavior. 53. 149–153. 8 indexed citations

Fisher, Robert S., George Nune, Sanford E. Roberts, & Joyce A. Cramer. (2014). The Personal Impact of Epilepsy Scale (PIES). Epilepsy & Behavior. 42. 140–146. 42 indexed citations

Krystal, John H., Robert A. Rosenheck, Joyce A. Cramer, et al.. (2011). Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service-Related PTSD. 11 indexed citations

Arzimanoglou, Alexis, et al.. (2010). The evolution of antiepileptic drug development and regulation. Epileptic Disorders. 12(1). 3–15. 50 indexed citations

Silverman, Stuart L., Deborah T. Gold, & Joyce A. Cramer. (2007). Reduced Fracture Rates Observed Only in Patients With Proper Persistence and Compliance With Bisphosphonate Therapies. Southern Medical Journal. 100(12). 1214–1218. 25 indexed citations

Rosen, Marc I., Kevin D. Dieckhaus, Thomas J. McMahon, et al.. (2007). Improved Adherence with Contingency Management. AIDS Patient Care and STDs. 21(1). 30–40. 147 indexed citations

Hughes, Dyfrig, Warren Cowell, Tamás Koncz, & Joyce A. Cramer. (2007). Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations. Value in Health. 10(6). 498–509. 86 indexed citations

Ettinger, Alan B., Michael L. Reed, & Joyce A. Cramer. (2004). Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology. 63(6). 1008–1014. 251 indexed citations

10.

Cramer, Joyce A.. (2003). Obtaining optimal compliance with drug therapy.. PubMed. 12(10 Suppl). 9–5. 4 indexed citations

11.

Lappalainen, Jaakko, Henry R. Kranzler, Robert T. Malison, et al.. (2002). A Functional Neuropeptide Y Leu7Pro Polymorphism Associated With Alcohol Dependence in a Large Population Sample From the United States. Archives of General Psychiatry. 59(9). 825–825. 128 indexed citations

12.

Cramer, Joyce A.. (2001). Exploration of Changes in Health-Related Quality of Life after 3 Months of Vagus Nerve Stimulation. Epilepsy & Behavior. 2(5). 460–465. 50 indexed citations

13.

Devinsky, Orrin & Joyce A. Cramer. (2000). Safety and efficacy of standard and new antiepileptic drugs.. PubMed. 55(11 Suppl 3). S5–10. 15 indexed citations

14.

Cramer, Joyce A. & Robert Rosenheck. (1999). Enhancing Medication Compliance for People with Serious Mental Illness. The Journal of Nervous and Mental Disease. 187(1). 53–55. 110 indexed citations

15.

Cramer, Joyce A., Lauren E. Westbrook, Orrin Devinsky, et al.. (1999). Development of the Quality of Life in Epilepsy Inventory for Adolescents: The QOLIE‐AD‐48. Epilepsia. 40(8). 1114–1121. 239 indexed citations

16.

Cramer, Joyce A., Kenneth Perrine, Orrin Devinsky, et al.. (1998). Development and Cross‐Cultural Translations of a 31‐Item Quality of Life in Epilepsy Inventory. Epilepsia. 39(1). 81–88. 600 indexed citations breakdown →

17.

Cramer, Joyce A., Kenneth Perrine, Orrin Devinsky, & Kimford J. Meador. (1996). A Brief Questionnaire to Screen for Quality of Life in Epilepsy The QOLIE‐10. Epilepsia. 37(6). 577–582. 316 indexed citations

18.

Cramer, Joyce A.. (1995). Partial Medical Compliance: The Enigma in Poor Medical Outcomes. The American Journal of Managed Care. 1. 11 indexed citations

19.

Mattson, Richard H. & Joyce A. Cramer. (1985). Epilepsy, Sex Hormones, and Antiepileptic Drugs. Epilepsia. 26(s1). S40–51. 132 indexed citations

20.

Chatot, Clare L., Norman W. Klein, Margie L. Clapper, et al.. (1984). Human Serum Teratogenicity Studied by Rat Embryo Culture: Epilepsy, Anticonvulsant Drugs, and Nutrition. Epilepsia. 25(2). 205–216. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact